# Effect of Essential Phospholipids in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Randomised Phase 4 Clinical Trial

## TL;DR

A clinical trial found that essential phospholipids, when added to standard care, reduced liver fat, fatigue, and blood sugar in patients with fatty liver disease and metabolic conditions.

## Contribution

This phase 4 trial provides strong evidence that essential phospholipids improve liver steatosis and metabolic parameters in MASLD patients.

## Key findings

- EPL significantly reduced liver fat (CAP score) compared to placebo at 3 and 6 months.
- EPL improved quality of life, particularly reducing fatigue in MASLD patients.
- EPL treatment also significantly improved HbA1c levels over 6 months.

## Abstract

Metabolic dysfunction‐associated steatotic liver disease (MASLD) poses a significant health burden and impacts quality of life (QoL). This study evaluates the effects of essential phospholipids (EPL) on liver steatosis, QoL, and other liver and metabolic parameters in patients with MASLD and associated comorbidities.

In this multicenter, double‐blind, randomised, placebo‐controlled phase 4 clinical trial, patients with MASLD and type 2 diabetes, hyperlipidemia, or obesity received either EPL or placebo, alongside standard of care. Primary endpoint: change in hepatic steatosis from baseline to 6 months (measured by Controlled Attenuation Parameter [CAP] score); secondary endpoints: changes in QoL (measured by the Chronic Liver Disease Questionnaire [CLDQ‐MASLD]), symptom changes; other endpoints: other liver, metabolic, and lipid parameters, and safety.

Of 193 randomised patients, 165 constituted the modified intention‐to‐treat population (median age: 56.5 years [EPL arm], 55.0 years [placebo arm]). More than ¾ of patients were obese and had CAP score ≥ 280 dB/m. At 6 months, EPL treatment significantly reduced CAP (p = 0.0269) versus placebo. This effect was evident at 3 months (p = 0.0049) and sustained until 3 months post treatment (p = 0.0234). QoL total score showed numerical improvement, with statistically significant improvement in fatigue subscore (p = 0.0229) with EPL versus placebo at 6 months. EPL significantly improved HbA1c levels (p = 0.0069) over 6 months. No safety concerns arose.

The beneficial effects of EPL on hepatic steatosis, QoL and glycemic control, and its favourable safety profile make it a promising candidate for managing steatosis and enhancing overall liver health in MASLD patients with cardiometabolic risk.

The trial was registered in the EudraCT (2021‐006069‐39)

Essential phospholipids (EPLs) can be used along with standard treatments to reduce liver fat in patients with fatty liver disease linked to metabolic health issues. However, strong evidence from well‐controlled studies is limited.The present phase 4 clinical study (EXCEL) found that EPLs, when added to standard care, significantly reduced liver fat, tiredness and blood sugar levels within 6 months in such patients.These results suggest that EPLs could be a safe and effective option to improve liver health in patients with fatty liver disease with conditions like diabetes, high cholesterol, or obesity.

Essential phospholipids (EPLs) can be used along with standard treatments to reduce liver fat in patients with fatty liver disease linked to metabolic health issues. However, strong evidence from well‐controlled studies is limited.

The present phase 4 clinical study (EXCEL) found that EPLs, when added to standard care, significantly reduced liver fat, tiredness and blood sugar levels within 6 months in such patients.

These results suggest that EPLs could be a safe and effective option to improve liver health in patients with fatty liver disease with conditions like diabetes, high cholesterol, or obesity.